# HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

> **NCT04627363** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Bevacizumab
- Liver Neoplasms
- Toripalimab
- Oxaliplatin

## Interventions

- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **DRUG:** Bevacizumab
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04627363
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627363, "HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04627363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*